...
首页> 外文期刊>Applied biochemistry and biotechnology, Part A. enzyme engineering and biotechnology >Expression of biologically active human recombinant interferon alpha 2b in human breast cancer cell line Bcap-37
【24h】

Expression of biologically active human recombinant interferon alpha 2b in human breast cancer cell line Bcap-37

机译:具有生物活性的人重组干扰素α2b在人乳腺癌细胞Bcap-37中的表达

获取原文
获取原文并翻译 | 示例
           

摘要

Human interferon alpha 2b (IFNα-2b) is a pleiotropic cytokine used to treat various viral diseases and cancers. Conventionally, recombinant human IFNα-2b used in clinics was produced by prokaryotic expression system, which always lack of enough biological activity due to limitations on proper folding and post-translational modifications, so the eukaryotic expression system are becoming prevailing method for the production of recombinant proteins. In this study, human breast cancer cell Bcap-37 was firstly used as host for the expression of human IFNα-2b, with the expression vector pIRES2-IFN-EGFP, in which IFNα-2b gene is under the control of CMV promoter. The expression of recombinant IFNα-2b was detected by Western blot and ELISA. Results showed that the concentration of the secreted recombinant IFNα-2b in culture medium was 435.7 pg/mL/24 h. Biological activity of the recombinant IFNα-2b was assayed by detecting the expression of IFN-inducible genes, including MxA, OAS, PKR, and Caspase1 through QRT-PCR. Results demonstrated that recombinant IFNα-2b possess the biological activities. Compared to non-transgenic cells, the expression levels of the aforementioned four IFN-inducible genes were increased by 18.098-, 1.843-, 2.21-, and 3.066-folds, respectively. We got to a conclusion that the human breast cancer cell Bcap-37 could express bioactive recombinant IFNα-2b.
机译:人干扰素α2b(IFNα-2b)是用于治疗各种病毒性疾病和癌症的多效细胞因子。通常,临床上使用的重组人IFNα-2b是通过原核表达系统产生的,由于适当的折叠和翻译后修饰的局限,该原核表达系统始终缺乏足够的生物学活性,因此,真核表达系统已成为生产重组体的主要方法。蛋白质。在这项研究中,人类乳腺癌细胞Bcap-37首先被用作表达IFNα-2b的宿主,表达载体为pIRES2-IFN-EGFP,其中IFNα-2b基因处于CMV启动子的控制之下。 Western blot和ELISA检测重组IFNα-2b的表达。结果显示,培养基中分泌的重组IFNα-2b的浓度为435.7 pg / mL / 24 h。通过QRT-PCR检测IFN诱导型基因(包括MxA,OAS,PKR和Caspase1)的表达来测定重组IFNα-2b的生物学活性。结果表明重组IFNα-2b具有生物学活性。与非转基因细胞相比,上述四个IFN诱导型基因的表达水平分别增加了18.098-,1.843-,2.21-和3.066-倍。我们得出的结论是,人乳腺癌细胞Bcap-37可以表达具有生物活性的重组IFNα-2b。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号